Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as [14C]-LY3871801
LY3871801 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| LY3871801 Phase 2a | EXPERIMENTAL | Participants will receive LY3871801 administered orally. |
| Placebo Phase 2a | PLACEBO_COMPARATOR | Participants will receive placebo. |
| LY3871801 Dose 1 Phase 2b | EXPERIMENTAL | Participants will receive LY3871801 administered orally. |
| LY3871801 Dose 2 Phase 2b | EXPERIMENTAL | Participants will receive LY3871801 administered orally. |
| LY3871801 Dose 3 Phase 2b | EXPERIMENTAL | Participants will receive LY3871801 administered orally. |
| Placebo Phase 2b | PLACEBO_COMPARATOR | Participants will receive placebo. |
| Name | Type | Description |
|---|---|---|
| LY3871801 | DRUG | Administered orally |
| Placebo | DRUG | Administered orally |
Inclusion Criteria: * Have a diagnosis of adult-onset RA for at least 3 months prior to screening as defined by the 2010 ACR/European League Against Rheumatism (EULAR) classification criteria. * Have moderately-to-severely active RA at screening and baseline, defined by the presence of * ≥6 swol...
Top 20 of 31 competitors
LY3871801 is being developed for the treatment of rheumatoid arthritis, an inflammatory autoimmune condition affecting the joints. It is an investigational small molecule studied in adults with rheumatoid arthritis. Eli Lilly and Company is developing the drug, and it has not been approved for any use.
LY3871801 is being developed by Eli Lilly and Company, which trades on the New York Stock Exchange under the ticker LLY. Lilly is the sponsor of the clinical program evaluating the drug in rheumatoid arthritis.
LY3871801 is in Phase 2 development. It has completed one Phase 2a/2b clinical trial in adults with rheumatoid arthritis. The drug remains investigational and has not been approved by the FDA or any other regulatory agency.
LY3871801 has been studied in one clinical trial, NCT05848258, titled An Adaptive Phase 2a/2b Study of LY3871801 in Adult Participants With Rheumatoid Arthritis. The trial enrolled 164 participants across the United States, Argentina, Czechia, France, Germany, Hungary, India, Mexico, Poland, and the United Kingdom, and it is now completed.
Yes, [14C]-LY3871801 is an alternative name for LY3871801. The [14C] label refers to a carbon-14 radiolabeled version of the same molecule, typically used in studies to track how the drug is absorbed, distributed, metabolized, and excreted.
The Phase 2a/2b trial NCT05848258 was a randomized, double-blind, placebo-controlled study in adults with rheumatoid arthritis. It enrolled 164 participants aged 18 years and older, included both sexes, and did not enroll healthy volunteers. The trial has been completed.